Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARICADE-PRESERVE baricitinib study in new-onset type 1 diabetes
NL-OMON59750Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Change from Baseline in C-peptide Area Under the Curve (AUC). Started Jul 2026; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON59750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59750.